Roivant Sciences Ltd.
ROIVHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Roivant Sciences Ltd. (ROIV) is listed under Biotechnology. Valued at $25.23B, ROIV is a large-cap name in its sector. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Market Cap
$25.23B
Beta
1.12
P/E (TTM)
—
P/E (Fwd)
-20.34
EPS (TTM)
$-0.47
EPS (Fwd)
$-1.72
ROE
-8.5%
ROA
-16.5%
Cash
$3.84B
Total Debt
$107.2M
Free CF
-$1.13B
52W Change
159.1%
Annual Financials
Cash vs Debt
Where ROIV stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ROIV finished 13.25% above its 150-day moving average ($30.48) and 22.07% above its 200-day moving average ($28.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ROIV overbought or oversold?
At the September 2, 2026 close, ROIV's RSI(14) was 38.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $3.84B in cash and $107.2M in debt, ROIV maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$1.13B. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -8.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $31.5M (2023) to $8.3M (2026), a 74% decline worth watching.
With cash comfortably exceeding debt, ROIV has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ROIV.